1. Home
  2. MODD vs RNTX Comparison

MODD vs RNTX Comparison

Compare MODD & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modular Medical Inc.

MODD

Modular Medical Inc.

HOLD

Current Price

$0.46

Market Cap

30.6M

Sector

Health Care

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.55

Market Cap

35.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MODD
RNTX
Founded
1998
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.6M
35.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MODD
RNTX
Price
$0.46
$1.55
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
248.4K
195.3K
Earning Date
02-12-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$1.02
52 Week High
$1.34
$3.50

Technical Indicators

Market Signals
Indicator
MODD
RNTX
Relative Strength Index (RSI) 55.50 66.46
Support Level $0.44 $1.12
Resistance Level $0.50 $1.25
Average True Range (ATR) 0.04 0.11
MACD 0.00 0.05
Stochastic Oscillator 47.84 84.91

Price Performance

Historical Comparison
MODD
RNTX

About MODD Modular Medical Inc.

Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: